Compare AGCO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGCO | IMVT |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.0B |
| IPO Year | 1994 | 2019 |
| Metric | AGCO | IMVT |
|---|---|---|
| Price | $121.21 | $39.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $119.09 | $33.00 |
| AVG Volume (30 Days) | 625.6K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 271.35 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $10,082,000,000.00 | N/A |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $154.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $99.21 | $14.32 |
| 52 Week High | $143.78 | $41.23 |
| Indicator | AGCO | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 55.86 |
| Support Level | $109.31 | $37.53 |
| Resistance Level | $121.00 | $41.23 |
| Average True Range (ATR) | 3.42 | 1.48 |
| MACD | 0.46 | -0.34 |
| Stochastic Oscillator | 98.37 | 41.08 |
Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealers and distribution locations and reaches into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its partnership with Rabobank of the Netherlands, having exited their JV in 2026.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.